186 related articles for article (PubMed ID: 29804123)
1. Aflibercept Treatment in Polypoidal Choroidal Vasculopathy: Results of a Prospective Study in a Caucasian Population.
Wolff B; Vasseur V; Cahuzac A; Coscas F; Castelnovo L; Favard C; Michel G; Français C; Salomon L; Mauget-Faÿsse M
Ophthalmologica; 2018; 240(4):208-212. PubMed ID: 29804123
[TBL] [Abstract][Full Text] [Related]
2. Timing of Complete Polypoidal Regression after Intravitreous Aflibercept Treatments in Polypoidal Choroidal Vasculopathy.
Chaikitmongkol V; Upaphong P; Patikulsila D; Jirarattanasopa P; Choovuthayakorn J; Watanachai N; Kunavisarut P; Ratanasukon M; Bhurayanontachai P; Ingviya T; Bressler SB; Bressler NM
Ophthalmol Retina; 2022 Jan; 6(1):21-28. PubMed ID: 33781929
[TBL] [Abstract][Full Text] [Related]
3. Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy.
Morimoto M; Matsumoto H; Mimura K; Akiyama H
Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):1891-1897. PubMed ID: 28669041
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy: 1-year results of the VAULT study.
Lee JE; Shin JP; Kim HW; Chang W; Kim YC; Lee SJ; Chung IY; Lee JE;
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):493-502. PubMed ID: 27628062
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy: Two-Year Results of the Aflibercept in Polypoidal Choroidal Vasculopathy Study.
Wong TY; Ogura Y; Lee WK; Iida T; Chen SJ; Mitchell P; Gemmy Cheung CM; Zhang Z; Leal S; Ishibashi T;
Am J Ophthalmol; 2019 Aug; 204():80-89. PubMed ID: 30849345
[TBL] [Abstract][Full Text] [Related]
6. One-year outcome of combination therapy with intravitreal aflibercept and verteporfin photodynamic therapy for polypoidal choroidal vasculopathy.
Matsumiya W; Honda S; Otsuka K; Miki A; Nagai T; Imai H; Kusuhara S; Nakamura M
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):541-548. PubMed ID: 27687988
[TBL] [Abstract][Full Text] [Related]
7. Initial treatment for polypoidal choroidal vasculopathy: Ranibizumab combined with photodynamic therapy or fixed-dosing aflibercept monotherapy.
Yoneda A; Wakiyama H; Kurihara J; Kitaoka T
Eur J Ophthalmol; 2020 Nov; 30(6):1473-1479. PubMed ID: 31476891
[TBL] [Abstract][Full Text] [Related]
8. Optic disk melanocytoma associated with polypoidal choroidal vasculopathy lesions, after combination treatment of photodynamic therapy and intavitreal aflibercept (Eylea), a case report.
Rouvas A; Gouliopoulos NS; Moschos MM; Theodossiadis P
BMC Ophthalmol; 2018 Oct; 18(1):267. PubMed ID: 30309335
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy.
Ogasawara M; Koizumi H; Yamamoto A; Itagaki K; Saito M; Maruko I; Okada AA; Iida T; Sekiryu T
Jpn J Ophthalmol; 2018 Sep; 62(5):584-591. PubMed ID: 29974277
[TBL] [Abstract][Full Text] [Related]
10. OPTICAL COHERENCE TOMOGRAPHY FEATURES OF POLYPOIDAL LESION CLOSURE IN POLYPOIDAL CHOROIDAL VASCULOPATHY TREATED WITH AFLIBERCEPT.
Tan ACS; Jordan-Yu JM; Vyas CH; Gan ATL; Teo KYC; Chan CM; Mathur R; Wong TY; Chakravarthy U; Cheung GCM
Retina; 2022 Jan; 42(1):114-122. PubMed ID: 34412103
[TBL] [Abstract][Full Text] [Related]
11. One-Year Outcomes following Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in Japanese Patients: The APOLLO Study.
Oshima Y; Kimoto K; Yoshida N; Fujisawa K; Sonoda S; Kubota T; Murata T; Sakamoto T; Yoshida S; Sonoda KH; Ishibashi T
Ophthalmologica; 2017; 238(3):163-171. PubMed ID: 28697497
[TBL] [Abstract][Full Text] [Related]
12. Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy.
Singh SR; Sahoo NK; Goud NR; Chhablani J
Indian J Ophthalmol; 2019 Jul; 67(7):1114-1118. PubMed ID: 31238423
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal aflibercept for submacular hemorrhage secondary to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
Kim JH; Kim CG; Lee DW; Yoo SJ; Lew YJ; Cho HJ; Kim JY; Lee SH; Kim JW
Graefes Arch Clin Exp Ophthalmol; 2020 Jan; 258(1):107-116. PubMed ID: 31741044
[TBL] [Abstract][Full Text] [Related]
14. CHOROIDAL THICKNESS AS A PROGNOSTIC FACTOR OF PHOTODYNAMIC THERAPY WITH AFLIBERCEPT OR RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
Sakurada Y; Sugiyama A; Tanabe N; Kikushima W; Kume A; Iijima H
Retina; 2017 Oct; 37(10):1866-1872. PubMed ID: 28002268
[TBL] [Abstract][Full Text] [Related]
15. Complete regression of branching vascular network in polypoidal choroidal vasculopathy by ranibizumab and photodynamic therapy, two case reports.
Iesato Y; Tanaka M; Murata M; Kitahara J; Hirano T; Kurenuma T; Yoshida N; Murata T
BMC Ophthalmol; 2018 Nov; 18(1):284. PubMed ID: 30390650
[TBL] [Abstract][Full Text] [Related]
16. Comparison of initial treatment between 3-monthly intravitreal aflibercept monotherapy and combined photodynamic therapy with single intravitreal aflibercept for polypoidal choroidal vasculopathy.
Kikushima W; Sakurada Y; Sugiyama A; Tanabe N; Kume A; Iijima H
Graefes Arch Clin Exp Ophthalmol; 2017 Feb; 255(2):311-316. PubMed ID: 27534663
[TBL] [Abstract][Full Text] [Related]
17. The 24-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy.
Nakai S; Matsumiya W; Keiko O; Miki A; Nakamura M; Honda S
Jpn J Ophthalmol; 2019 Jan; 63(1):100-108. PubMed ID: 30406511
[TBL] [Abstract][Full Text] [Related]
18. Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience.
Bansal A; Bhende M; Sharma T; Bhende P; Mukherjee S
Indian J Ophthalmol; 2017 Aug; 65(8):758-760. PubMed ID: 28820169
[TBL] [Abstract][Full Text] [Related]
19. INTRAVITREAL AFLIBERCEPT IN THE TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY ASSOCIATED WITH MORNING GLORY SYNDROME.
Iovino C; Fossarello M; Peiretti E
Retin Cases Brief Rep; 2020; 14(3):278-281. PubMed ID: 29324624
[TBL] [Abstract][Full Text] [Related]
20. One-year outcomes of half-fluence photodynamic therapy combined with intravitreal injection of aflibercept for pachychoroid neovasculopathy without polypoidal lesions.
Matsumoto H; Mukai R; Kikuchi Y; Morimoto M; Akiyama H
Jpn J Ophthalmol; 2020 Mar; 64(2):203-209. PubMed ID: 32016666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
